程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习

夏涌, 寇晓霞, 杨喜晶, 周福平, 张迁, 钱其军

文章导航 > 药学实践与服务 > 2017 > 35(2): 174-177

夏涌, 寇晓霞, 杨喜晶, 周福平, 张迁, 钱其军. 程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习[J]. 药学实践与服务, 2017, 35(2): 174-177. doi: 10.3969/j.issn.1006-0111.2017.02.020

引用本文:

夏涌, 寇晓霞, 杨喜晶, 周福平, 张迁, 钱其军. 程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习[J]. 药学实践与服务, 2017, 35(2): 174-177. doi: 10.3969/j.issn.1006-0111.2017.02.020

XIA Yong, KOU Xiaoxia, YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 174-177. doi: 10.3969/j.issn.1006-0111.2017.02.020

Citation:

XIA Yong, KOU Xiaoxia, YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 174-177. doi: 10.3969/j.issn.1006-0111.2017.02.020

程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习

doi: 10.3969/j.issn.1006-0111.2017.02.020

第二军医大学附属东方肝胆外科医院生物治疗科, 上海 201805

Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor

Department of Bio-therapy, Eastern Hepatobiliary Surgical Hospital Affiliated to Second Military Medical University, Shanghai 201805, China

摘要: 目的观察程序死亡受体1（programmed death-1，PD-1）抗体治疗晚期肿瘤患者的免疫疗效。方法选取东方肝胆外科医院生物治疗科2015年10月至2016年3月的18例晚期肿瘤患者，给予PD-1抗体静滴治疗。观察患者治疗前后的临床疗效、不良反应及无进展生存期，并对治疗前后患者的生活质量进行对比。结果患者经PD-1抗体治疗后，PR 5例、SD 7例、PD 6例，生活质量KPS评分较治疗前明显上升（P<0.05）。至随访结束，共有5例死亡，2例失访，11例存活，中位无进展生存期为2.6个月（95% CI：1.8~3.3个月），无严重不良反应和化验指标异常。结论 PD-1抗体是治疗晚期肿瘤安全有效的治疗方法，不良反应少，临床耐受良好，但该结论仍有待进一步大样本随机对照研究证实。
- PD-1抗体 /
- 晚期肿瘤 /
- 肿瘤免疫治疗
Abstract: Objective To observe the immune effect of PD-1 (programmed death-1) antibody in the treatment of patients with advanced cancer. Methods From October 2015 to March 2016, 18 patients with advanced tumor were selected to receive the PD-1 antibody treatment in Eastern Hepatobiliary Surgical Hospital. Clinical efficacy, adverse reactions and progression free survival time were monitored. The quality of life were compared before and after the treatment. Results Among 18 cases, PR 5 cases, SD 7 cases and PD 6 cases. The KPS scores for quality of life was significantly increased (P<0.05) after treatment. At the end of follow-up, 5 patients died, 2 patients were lost in follow-up, 11 patients survived. The median progression free survival was 2.6 months (95% CI:1.8-3.3 months). No serious adverse reactions and abnormal laboratory results were reported. Conclusion PD-1 antibody is a safe and effective treatment for advanced tumors. It is well tolerated and has less adverse reactions. The randomized control studies with larger samples are needed to further confirm our conclusions.
- PD-1 antibody /
- advanced tumor /
- tumor immunotherapy

[1]	de Koning HJ, Meza R,Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies:a comparative modeling study for the U.S. Preventive Services Task Force[J]. Ann Intern Med,2014,160(5):311-320.
[2]	Rucci N,Angelucci A.Postate cancer and bone:the elective affinities[J]. Biomed Res Int,2014,2014:167035.
[3]	Zuo TT, Zheng RS, Zhang SW, et al. Incidence and mortality of liver cancer in China in 2011[J]. Chin J Cancer,2015,34(11):508-513.
[4]	Kirkwood JM, Butterfield LH, Tarhini AA,et al. Immunotherapy of cancer in 2012[J]. CA Cancer J Clin,2012,62(5):309-335.
[5]	Zak KM, Grudnik P, Guzik K, et al. Structural basis for small molecule targeting of the programmed death ligand 1(PD-L1)[J]. Oncotarget,2016,7(21):30323- 30335.
[6]	Muenst S, Läubli H, Soysal SD,et al.The immune system and cancer evasion strategies:therapeutic concepts[J]. J Intern Med,2016,279(6):541-562.
[7]	Trivedi MS, Hoffner B, Winkelmann JL,et al.Programmed death 1 immune checkpoint inhibitors[J]. Clin Adv Hematol Oncol,2015,13(12):858-868.
[8]	Chakravarti N, Prieto VG. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs:immunohisto chemistry analysis[J]. Transl Lung Cancer Res,2015,4(6):743-751.
[9]	Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J]. J Clin Oncol,2014,32(10):1020-1030.
[10]	Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med,2015,373(1):23-34.
[11]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med,2015,373(17):1627-1639.
[12]	Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015,373(19):1803-1813.
[13]	Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med,2012,366(26):2455-2465.

[1]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[2]	陈金涛, 乔子婴, 马明华, 张若曦, 王振伟, 年华. 基于网络药理学和分子对接技术研究金芪清疏颗粒治疗社区获得性肺炎的潜在机制 . 药学实践与服务, 2024, 42(11): 471-478. doi: 10.12206/j.issn.2097-2024.202312014
[3]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[4]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[5]	丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉. 消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
[6]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
[7]	景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞. 黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
[8]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
[9]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[10]	陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼. 通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
[11]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
[12]	顾佳钰, 胡馨儿, 王晓飞, 张颖, 张海, 曹岩. 侧流免疫层析定量检测方法的研究进展 . 药学实践与服务, 2024, 42(7): 273-277, 284. doi: 10.12206/j.issn.2097-2024.202307037
[13]	岳春华, 贲永光, 王海桥. 基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
[14]	李想, 陆鸿远, 张明玉, 高欢, 姚东, 许子华. 米格列醇激活UCP1介导棕色脂肪对冷暴露小鼠损伤的研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404005
[15]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
[16]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[17]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[18]	马兹芬, 许维恒, 金煜翔, 薛磊. 食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008

WeChat

点击查看大图

计量

文章访问数: 2999
HTML全文浏览量: 353
PDF下载量: 404
被引次数: 0

程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习

doi: 10.3969/j.issn.1006-0111.2017.02.020

第二军医大学附属东方肝胆外科医院生物治疗科, 上海 201805

收稿日期: 2016-04-28
修回日期: 2016-12-07

关键词:

肿瘤免疫治疗

摘要: 目的观察程序死亡受体1（programmed death-1，PD-1）抗体治疗晚期肿瘤患者的免疫疗效。方法选取东方肝胆外科医院生物治疗科2015年10月至2016年3月的18例晚期肿瘤患者，给予PD-1抗体静滴治疗。观察患者治疗前后的临床疗效、不良反应及无进展生存期，并对治疗前后患者的生活质量进行对比。结果患者经PD-1抗体治疗后，PR 5例、SD 7例、PD 6例，生活质量KPS评分较治疗前明显上升（P<0.05）。至随访结束，共有5例死亡，2例失访，11例存活，中位无进展生存期为2.6个月（95% CI：1.8~3.3个月），无严重不良反应和化验指标异常。结论 PD-1抗体是治疗晚期肿瘤安全有效的治疗方法，不良反应少，临床耐受良好，但该结论仍有待进一步大样本随机对照研究证实。

English Abstract

夏涌, 寇晓霞, 杨喜晶, 周福平, 张迁, 钱其军. 程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习[J]. 药学实践与服务, 2017, 35(2): 174-177. doi: 10.3969/j.issn.1006-0111.2017.02.020

引用本文:

夏涌, 寇晓霞, 杨喜晶, 周福平, 张迁, 钱其军. 程序死亡受体1抗体治疗18例晚期肿瘤患者的临床疗效观察及文献复习[J]. 药学实践与服务, 2017, 35(2): 174-177. doi: 10.3969/j.issn.1006-0111.2017.02.020

XIA Yong, KOU Xiaoxia, YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 174-177. doi: 10.3969/j.issn.1006-0111.2017.02.020

Citation:

XIA Yong, KOU Xiaoxia, YANG Xijing, ZHOU Fuping, ZHANG Qian, QIAN Qijun. Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(2): 174-177. doi: 10.3969/j.issn.1006-0111.2017.02.020

全文HTML

参考文献 (13)

/

下载: 全尺寸图片幻灯片

分享

用微信扫码二维码

分享至好友和朋友圈

返回

版权所有：《药学实践与服务》编辑委员会

主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号沪ICP备05003363号-1

本系统由北京仁和汇智信息技术有限公司开发